Levepsy 250 Tablet contains Levetiracetam 250 mg, an antiepileptic medication primarily indicated for the treatment of partial-onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in patients with epilepsy. Levetiracetam acts by modulating synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A, thereby stabilizing neuronal activity and reducing seizure frequency. This medication is commonly used as adjunctive therapy in adults and pediatric patients aged one month and older. Levepsy 250 Tablet is well-absorbed orally, with rapid onset of action and minimal hepatic metabolism, reducing the risk of drug interactions. It is generally well-tolerated; however, common adverse effects may include dizziness, somnolence, fatigue, and behavioral changes such as irritability or mood swings. Dose adjustment may be necessary in patients with renal impairment. Levepsy should be administered under strict medical supervision, with gradual dose titration to minimize side effects and optimize therapeutic efficacy. Patients are advised not to discontinue therapy abruptly to avoid increased seizure risk. Regular monitoring and adherence to prescribed dosing schedules are essential for effective seizure control and improved quality of life.